NHS Cancer Waiting Times Hit Record High

More than 300,000 people in England are currently waiting beyond the NHS's 62-day target to begin cancer treatment following an urgent referral, according to NHS England data — a figure that health experts describe as the highest sustained backlog in the health service's history. The scale of the crisis is prompting renewed calls from oncologists, patient charities, and senior NHS officials for urgent structural reform to diagnostic and referral pathways.

The 62-day standard, which requires patients to receive their first definitive cancer treatment within 62 days of an urgent GP referral, has not been met consistently at a national level for several years. However, data analysed this year show the proportion of patients being treated within that window has fallen to its lowest recorded level, with performance figures indicating that fewer than 65 percent of patients are receiving timely treatment — against the NHS target of 85 percent. (Source: NHS England)

The Scale of the Backlog

NHS England's most recent published data confirm that the total number of people waiting to start cancer treatment continues to rise. Urgent referrals for suspected cancer — commonly known as two-week wait referrals — are running at record volumes, partly reflecting improved awareness campaigns and post-pandemic catch-up demand. Yet diagnostic and treatment capacity has not kept pace with that demand, officials said.

Two-Week Wait Referrals at Record Volume

Two-week wait referrals from GPs have increased substantially over recent years, with NHS England recording over three million such referrals processed annually — a figure that represents a significant increase compared to pre-pandemic levels. While higher referral volumes are broadly positive from a public health standpoint, as they indicate earlier clinical suspicion and engagement, the diagnostic infrastructure required to process them has not expanded at the same rate, according to analysis published by The King's Fund.

For context on the broader NHS pressures contributing to these delays, including GP workforce constraints that affect the volume and speed of onward referrals, see our coverage of NHS waiting times hitting record highs as GP shortages worsen and the parallel crisis in NHS GP shortages driving waiting time crises.

Diagnostic Capacity Under Strain

Endoscopy, imaging, and pathology services sit at the heart of the cancer diagnostic bottleneck. NHS England's own Diagnostics Recovery and Transformation Programme has acknowledged that demand for CT, MRI, and endoscopic procedures exceeds available slots at many NHS trusts. The Royal College of Radiologists has previously warned of a shortage of consultant radiologists, estimating a shortfall running into the hundreds of posts nationally, which directly affects the speed at which suspicious findings can be reported and acted upon. (Source: Royal College of Radiologists)

Which Cancers Are Most Affected

Not all cancer pathways are equally affected by waiting time pressures. Data from NHS England's monthly cancer waiting times reports indicate that lung cancer, lower gastrointestinal cancer, and gynaecological cancers are among the tumour types with the poorest performance against the 62-day standard. These tend to be cancers that require complex multi-disciplinary assessment and are often diagnosed at a later stage, factors that extend the time between referral and treatment readiness.

Lung and Colorectal Pathways

Lung cancer, the leading cause of cancer death in the United Kingdom, has historically struggled to meet the 62-day standard due in part to the complexity of staging investigations required before treatment decisions can be made. Thoracic multidisciplinary teams, which bring together respiratory physicians, oncologists, thoracic surgeons, and radiologists, require coordination across multiple departments — and any delay at one node in the pathway can cascade into a significant overall delay for the patient.

Colorectal cancer pathways face similar pressures. Endoscopy waiting lists remain elevated, and colonoscopy capacity — the cornerstone of lower GI investigation — has struggled to recover fully following the pandemic. The BMJ has reported that late-stage colorectal cancer diagnoses increased during the period of diagnostic service disruption, a trend that treatment delays risk compounding. (Source: BMJ)

For more detail on previous threshold breaches and historical context, read our earlier reporting on how NHS cancer waiting times breached the 62-week threshold.

Impact on Patient Outcomes

The clinical consequences of prolonged waiting times are well-documented in peer-reviewed literature. A study published in The Lancet Oncology found that for most solid tumour types, each four-week treatment delay is associated with an approximate 10 percent increase in mortality risk. The relationship between delay and harm is not uniform across all cancer types — some haematological malignancies are particularly time-sensitive, while certain low-grade tumours may be less acutely affected — but the general principle that earlier treatment improves outcomes is supported by substantial evidence. (Source: The Lancet Oncology)

Psychological Impact on Patients

Beyond clinical outcomes, prolonged uncertainty carries a significant psychological burden. Research published in the BMJ Open has found that cancer patients waiting beyond recommended timeframes report substantially elevated rates of anxiety, depression, and diminished quality of life compared to those treated within target windows. Patient advocacy organisations including Macmillan Cancer Support and Cancer Research UK have called for both systemic investment and improved patient communication to mitigate this harm during periods of delay. (Source: BMJ Open)

Those waiting for other forms of NHS treatment face analogous pressures across the health service. Our wider coverage of NHS waiting lists hitting record highs amid the staff crisis sets the cancer backlog in its broader institutional context.

What NHS England and Government Have Said

NHS England officials have acknowledged the scale of the challenge, with the national cancer programme committing to a series of recovery milestones aimed at improving 62-day performance. The government's elective recovery plan includes investment in community diagnostic centres — standalone diagnostic hubs designed to increase the throughput of scans and tests outside of acute hospital settings — with the aim of adding millions of additional diagnostic appointments annually.

NICE has updated its guidance on suspected cancer referral pathways, emphasising that primary care clinicians should use structured clinical decision tools and risk stratification to ensure the highest-risk patients are referred most urgently. The guidance is designed to help manage high referral volumes while maintaining focus on clinical need. (Source: NICE)

The World Health Organization has separately flagged cancer care backlogs as a significant post-pandemic public health risk across high-income countries, noting that disruption to screening, diagnosis, and treatment services will have measurable effects on cancer mortality statistics for years to come. (Source: WHO)

Previous Coverage and Ongoing Trajectory

This is not the first time cancer waiting time performance has been flagged as a critical concern. As detailed in our earlier report on NHS cancer treatment delays hitting an 18-month high, the deterioration in waiting time performance has been a sustained trend rather than a sudden event, shaped by workforce shortages, infrastructure deficits, and the lasting effects of pandemic-era service disruption.

Community Diagnostic Centres: Promise and Progress

The rollout of community diagnostic centres has been cited by NHS England as a central plank of the recovery strategy. Approximately 160 such centres are currently operational across England, with NHS England data suggesting they have collectively delivered tens of millions of tests, checks, and scans since the programme launched. Independent health analysts at the Nuffield Trust and The King's Fund have broadly welcomed the initiative while cautioning that the centres alone cannot resolve backlogs driven by workforce shortages and retention difficulties in specialist cancer disciplines. (Source: NHS England; Nuffield Trust)

What the Public Should Know: Recognising Cancer Symptoms

Health officials and cancer charities consistently emphasise that individuals should not be deterred from presenting to their GP by awareness of NHS pressures. Earlier presentation remains one of the most powerful individual-level factors in improving cancer outcomes, and the NHS's two-week wait system is designed specifically to prioritise patients with symptoms suggestive of cancer.

NICE guidelines identify the following as symptoms that should prompt urgent GP review and potential cancer referral:

• Unexplained weight loss over a period of weeks
• Persistent fatigue not explained by lifestyle or other conditions
• A new or changing lump anywhere on the body
• Unexplained bleeding, including coughing up blood, blood in urine, or rectal bleeding
• Persistent cough lasting more than three weeks, particularly in current or former smokers
• Difficulty swallowing or persistent indigestion not responsive to standard treatment
• Changes in bowel habit, including persistent loose stools or constipation, lasting more than three weeks
• Unexplained pain that is persistent and has no obvious cause
• Skin changes, including new or altered moles or lesions that bleed, itch, or change in shape
• Night sweats that are severe or persistent

People experiencing any of the above symptoms are advised to contact their GP promptly, according to NHS guidance. Individuals should also continue to attend national cancer screening programmes — including bowel, breast, and cervical screening — for which invitations are sent by NHS England. (Source: NHS England)

The NHS cancer waiting times crisis reflects a convergence of long-term structural pressures — workforce, infrastructure, and demand — that have resisted resolution through incremental measures. While government investment in diagnostic capacity and the community diagnostic centre programme represent substantive responses, independent health economists and oncologists have consistently argued that meeting the 85 percent 62-day standard will require a more comprehensive workforce expansion strategy, sustained over multiple years. Until performance against that target is reliably restored, tens of thousands of patients will continue to face the documented clinical and psychological harms associated with delayed cancer care.